Self Focus in Bipolar Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study

NCT ID: NCT02253225

Last Updated: 2021-09-01

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 32 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-01-31
• Study Completion Date: 2020-01-31

Brief Summary

The investigators propose to examine both resting state activity and functional activity during rumination and during self-processing to study the relationship between neural correlates of rumination/self-focus and self-processing in major depression and bipolar disorder.

Detailed Description

Negative rumination, a specific form of self-focus, characterized by repetitively focusing on one's symptoms of distress, and the possible causes and consequences of these symptoms, is a hallmark of depression. Nearly a decade of research has culminated in evidence that the tendency to engage in negative rumination is highly correlated with depressive symptoms. Rumination also plays a critical role in the etiology and maintenance of depressed states and predicts risk for mania in bipolar disorder. Despite the central role of rumination in major depression and bipolar disorder, there have been few studies to date investigating the functional neuroanatomy of negative rumination, and no studies of positive rumination. The few neuroimaging studies that have utilized measures of the tendency to engage in negative rumination have focused on brain functioning when performing tasks that involve processing emotional or self-referential stimuli, but they have not studied resting state activity or functional activity during negative and positive rumination. We are examining both resting state activity and functional activity during negative and positive rumination and during self-processing to study the relationship between the neural correlates of rumination/self-focus and self-processing in major depression and bipolar disorder.

Conditions

Bipolar Disorder; Major Depression; Rumination

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Bipolar Disorder

Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 patients with bipolar disorder (BPAD).

Functional Magnetic Resonance Imaging (fMRI)

Intervention Type: OTHER

Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.

Major Depressive Disorder

Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 patients with major depression (MDD).

Functional Magnetic Resonance Imaging (fMRI)

Intervention Type: OTHER

Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.

Healthy Control

Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 normal, healthy volunteers.

Functional Magnetic Resonance Imaging (fMRI)

Intervention Type: OTHER

Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.

Interventions

Functional Magnetic Resonance Imaging (fMRI)

Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Right-handed (as determined by the Handedness Inventory; Oldfield, 1971)
• Normal or corrected-to normal vision and hearing

• Current diagnosis of MDD
• Right-handed (as determined by the Handedness Inventory; Oldfield, 1971)
• Normal or corrected-to normal vision and hearing

• Current diagnosis of BPAD
• Right-handed (as determined by the Handedness Inventory; Oldfield, 1971)
• Normal or corrected-to normal vision and hearing

Exclusion Criteria

• Any current or past psychiatric history
• Significant medical, psychiatric or neurological illness
• Currently taking antidepressants, mood stabilizers, or benzodiazepines
• Positive MR screen (e.g., metal implant, claustrophobia, etc)

• If a history of substance abuse, at least 6 months in remission
• Current suicidal ideation or history of suicide attempts
• Positive MR screen (e.g., metal implant, claustrophobia, etc)

• If a history of substance abuse, at least 6 months in remission
• Current suicidal ideation or history of suicide attempts
• Positive MR screen (e.g., metal implant, claustrophobia, etc)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Brain & Behavior Research Foundation

OTHER

Sponsor Role: collaborator

Massachusetts General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Sharmin Ghaznavi

Staff Psychiatrist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Sharmin Ghaznavi, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Locations

Massachusetts General Hospital

Boston, Massachusetts, United States

Countries

United States

Other Identifiers

19531

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2012P000714

Identifier Type: -

Identifier Source: org_study_id